Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms JNJ 78306358, JNJ-78306358 |
Target |
Action stimulants, modulators |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), HLA-G modulators(major histocompatibility complex, class I, G modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | Israel | 24 Oct 2021 | |
Advanced Malignant Solid Neoplasm | Phase 1 | Spain | 24 Oct 2021 |
Phase 1 | Ovarian Cancer | Advanced Malignant Solid Neoplasm | Renal Cell Carcinoma ... human leukocyte antigen-G (HLA-G) View more | 39 | uxbalsptln(gstwlsgxbz) = giovszkrtr iwfoupfejq (yfqbectpfa ) View more | Positive | 06 Aug 2024 |